PFS increase but no OS increase for niraparib in advanced ovarian cancer
4:19
Watchful waiting vs intravesical BCG in high grade pT1 bladder cancer
6:31
PRIMA: Frontline Niraparib Maintenance Therapy in Ovarian Cancer
24:35
ESMO 2024: Highlights and analysis
4:27
Nivolumab and ipilimumab shows a significantly higher OS rate in nccRCC compared to standard of ...
58:46
Learn all about PARP inhibitors with Dr Jon Krell, Consultant Medical Oncologist
2:19:51
Uzak Şehir 11. Bölüm
57:11
Personalizing Advanced Ovarian Cancer Treatment With PARP Inhibitors and Novel Approaches
17:18